Timing of radiation plus immunotherapy could be key to antitumor response in kidney cancer

Reuters Health - 15/09/2020 - Appropriate timing of radiation and immunotherapy likely will improve the antitumor response in kidney cancer, a high-throughput analysis suggests. "We are still learning how radiation... alters existing patient immune responses," Dr. Jason Muhitch of Roswell Park Comprehensive Cancer Center in Buffalo, New York told Reuters Health by email. "We are also finding that the factors that influence patient responses to treatment can be specific for tumor types. Therefore, additional work is needed to show if the endpoints utilized in our study are reliable indicators for the specific forms of immunotherapy used in kidney cancer." As reported in Proceedings of the National Academy of Sciences of the United States of America (PNAS), Dr. Muhitch and colleagues analyzed kidney cancer cell samples from patients treated with stereotactic body radiation therapy (SBRT). Pathway analysis showed that SBRT is an effective immune-sensitizing agen...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 15 September, 202030 September, 2020